SCHEMBL5535149

SCHEMBL5535149

COc1ccc(-c2cc[c]nc2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
PDE4A P27815 1/20 0.44
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 4/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ERN1 O75460 1/20 0.43
HPGD P15428 2/20 0.41
MAPK1 P28482 2/20 0.41
GAK O14976 2/20 0.41
KIT P10721 1/20 0.41
DYRK1A Q13627 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
GAA P10253 1/20 0.41
MPI P34949 1/20 0.41
GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2751271 0.87 ADORA2A (0.42) PDGFRBPDGFRAALDH1A1ERN1DYRK1A
SCHEMBL5207753 0.80 PDGFRB (0.51) PDGFRBPDGFRAPDE4AALDH1A1KDM4E
SCHEMBL8840880 0.77 PDE4A (0.67) PDGFRBPDGFRAPDE4AALDH1A1KDM4E
SCHEMBL743735 0.77 ESR2 (0.45) PDGFRBPDGFRAKDM4ENPC1RAB9A
SCHEMBL28467263 0.76 PDE4A (0.52) PDGFRBPDGFRAPDE4AALDH1A1KDM4E
SCHEMBL322590 0.76 PDE4A (0.52) PDGFRBPDGFRAPDE4AALDH1A1KDM4E
SCHEMBL14438060 0.75 PDGFRB (0.58) PDGFRBPDGFRAPDE4AGAKKIT
SCHEMBL744972 0.75 DYRK1A (0.49) PDGFRBPDGFRADYRK1ACYP3A4
SCHEMBL745572 0.74
SCHEMBL2750448 0.73 CA2 (0.48) PDGFRBPDGFRAALDH1A1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PDGFRB 4062/4885PDGFRA 4209/4885PDE4A 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.